This week showed how far apart peptide policy and peptide practice still are. On October 20 and 21, Health Secretary Robert F. Kennedy Jr. and a sitting U.S. senator both pushed the FDA to move faster on letting pharmacies compound certain peptides, with the senator proposing the most specific guardrails floated so far. Days earlier, a North Carolina pharmacy recalled compounded tirzepatide and NAD+ vials nationwide because it couldn’t confirm they were made under sterile conditions — a plain illustration of what those guardrails exist to prevent.
Kennedy and a Senator Push FDA to Move Faster on Peptide Compounding
Speaking on Fox News on October 20, 2026, Kennedy argued that Americans will keep buying unapproved peptides regardless of what the FDA decides, so the better path is a market where those products are made in inspected facilities and actually match their labels. “Americans are going to be buying these anyway,” he said. His comments build on the “Interim Access Policy for Compounding Using Certain Peptides” that the FDA submitted to the White House Office of Management and Budget on October 14 — a filing that discloses no specifics but is widely read as a step toward enforcement discretion for a defined set of peptides, including BPC-157.
The next day, Senator Roger Marshall, a Kansas Republican and physician, sent a letter to Acting FDA Commissioner Kyle Diamantas urging the agency to use that enforcement-discretion approach now, arguing current restrictions push patients toward unregulated sellers. His letter proposed four interim conditions: ingredients sourced from FDA-registered, cGMP-compliant facilities; compounding only at registered outsourcing facilities or state-licensed 503A pharmacies; a prescription for an identified patient on every product; and ongoing safety-data review with the FDA’s Pharmacy Compounding Advisory Committee (PCAC).
Why It Matters
Marshall’s letter is the most concrete public framework anyone has floated for what “enforcement discretion” might require, while the actual OMB filing remains undisclosed. It also shows a split in framing: Kennedy’s argument is about access (patients will buy these anyway), while Marshall’s is about guardrails (specific sourcing and prescribing conditions). Which version shapes the final policy will decide whether faster access also means safer access — the question the next story makes concrete.
A Licensed Pharmacy’s Sterility Recall Shows What the Guardrails Are For
Apothecary Pharma LLC, a 503B outsourcing facility in Cary, North Carolina, voluntarily recalled 22 lots of its compounded tirzepatide injection (18 mg/mL, in 4 mL multi-dose vials) and one lot of its NAD+ injection nationwide. The company began the recall on September 24, and the FDA posted it as a Class II recall on October 8 — news outlets including Becker’s Hospital Review and Managed Healthcare Executive were still covering as recently as October 20 and 21. The stated reason is a “lack of assurance of sterility”: the firm could not confirm its process reliably kept the products sterile, which is distinct from confirming contamination was actually found. The FDA had previously sent Apothecary Pharma a warning letter describing serious deficiencies in its sterile drug practices, including personnel with exposed skin in an aseptic processing area. No adverse events have been tied specifically to this recall, though the FDA separately counts nearly 1,700 cumulative adverse-event reports linked to compounded semaglutide and tirzepatide broadly, which it says are likely undercounted.
Why It Matters
Apothecary Pharma is not a gray-market seller — it’s a 503B outsourcing facility, the type of FDA-registered, larger-scale compounder that proposals like Marshall’s point to as the legitimate alternative to unregulated imports. A sterility failure at that level is a reminder that “FDA-registered” and “state-licensed” describe who may legally compound a drug, not whether a given batch was actually made under sterile conditions. If the compounding list grows to include more peptides, sterility oversight will matter just as much as which peptides are legally on it.
Where the Compounding Review Stands
The FDA’s interim access policy remains under White House review with no public text or timeline, following its October 14 submission. The PCAC’s July 2026 recommendation of six peptides for the 503A bulk list — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — still hasn’t moved through formal rulemaking, and a second, larger PCAC review of additional peptides is still expected before February 2027. The Seventh Circuit hasn’t ruled on retatrutide’s drug-versus-biologic classification since oral argument on September 24 — now a month out, which we covered last week — and the EVEXIAS Life Sciences lawsuit against the FDA’s “Category 2” peptide restrictions also remains unresolved.
How to Check Whether a Compounded Prescription You’ve Received Is Part of a Recall
A recall notice only helps if you can tell whether it applies to you:
- Get the exact product name, NDC number, and lot number from your pharmacy label, not just the drug name — recalls are issued by specific lot.
- Search the FDA’s recall and enforcement database (accessdata.fda.gov) or ask your pharmacy directly whether your lot is affected.
- Call your prescribing physician before stopping or changing anything if you find a match, so the decision fits your situation rather than being made alone.
- Report symptoms you associate with a compounded product to the FDA’s MedWatch system — that’s also how patterns like sterility problems get surfaced in the first place.
What This Means for Patients
- Talk to a licensed physician before starting any peptide or hormone therapy, so someone with your full health history, not a product page, weighs the risks.
- Use only licensed U.S. pharmacies for anything compounded, and don’t assume “licensed” status alone means a given batch was made correctly — recalls happen inside the legal system too.
- Avoid products labeled “research use only” or sold with no prescription. That label doesn’t change the legal status or safety profile of what’s inside the vial.
FAQ
What did Kennedy say about peptides this week?
On October 20, 2026, in a Fox News interview, Health Secretary Robert F. Kennedy Jr. said Americans will buy unapproved peptides regardless of FDA restrictions, so the administration’s goal is a market where those products are made in inspected facilities and match their labels.
What did Senator Marshall ask the FDA to do?
On October 21, 2026, Senator Roger Marshall sent a letter to Acting FDA Commissioner Kyle Diamantas urging enforcement discretion for peptide compounding now, under conditions including FDA-registered ingredient sourcing, compounding only at registered or licensed facilities, patient-specific prescriptions, and ongoing safety review with the FDA’s advisory committee.
What happened with the Apothecary Pharma recall?
Apothecary Pharma LLC, a North Carolina 503B outsourcing facility, recalled 22 lots of compounded tirzepatide injection and one lot of NAD+ injection nationwide after it couldn’t confirm the products were sterile. The FDA classified it as a Class II recall on October 8, 2026. No adverse events have been reported in connection with this specific recall.
Does a pharmacy being “licensed” or “FDA-registered” mean its products are safe?
Not automatically. Licensing and registration establish that a pharmacy is legally permitted to compound drugs and is subject to inspection, but they do not confirm that every batch was manufactured correctly. The Apothecary Pharma recall involved a registered 503B facility, which is why sterility audits and enforcement matter alongside licensing status.
Has the Seventh Circuit ruled on retatrutide’s legal classification?
No. The court heard oral argument on September 24, 2026, and has not issued a decision. Appellate rulings of this kind typically take weeks to months.
This article is for informational purposes only and does not constitute medical advice. Prestigious Health does not sell, offer or prescribe products that lack FDA approval or a lawful compounding pathway.
Sources
- iHeartRadio — RFK Jr. Calls For Regulated Peptide Marketplace (October 21, 2026)
- Alliance for Pharmacy Compounding — Two Calls for Peptide Access in Two Days
- Becker’s Hospital Review — Compounded GLP-1 Injections Recalled Nationwide: 4 Notes (October 20, 2026)
- Managed Healthcare Executive — Apothecary Pharma Recalls Compounded Tirzepatide and NAD+ Vials Over Sterility Concerns (October 21, 2026)
- FDA Enforcement Report — Apothecary Pharma Recall Listing
- Buchanan Ingersoll & Rooney — FDA Submits Interim Peptide Compounding Policy for White House Review: What Pharmacies Should Know (October 22, 2026)